Granted Patent
B2
US 12,714,681 · App. 19/435,712 · Granted Aug 25, 2026
Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation
View Patent ↗
Loading inventors, assignments & file history…
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 12, 2026
From: COPE, STEVEN M.; TITUS, ALLEN E.
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 074942/0446 →
Continuity (4)
Provisional Application
62986606
· Mar 6, 2020
References Cited (61)
US 5849843A
· Laurin et al.
· 1998
[cited by applicant]
US 5998019A
· Rosenbaum et al.
· 1999
[cited by applicant]
US 6613036B1
· Farmer et al.
· 2003
[cited by applicant]
US 20010008686A1
· Inoue et al.
· 2001
[cited by applicant]
US 20040000219A1
· McNulty
· 2004
[cited by applicant]
US 20080249499A1
· Vancaillie et al.
· 2008
[cited by applicant]
US 20090044700A1
· Dietlin et al.
· 2009
[cited by applicant]
US 20100247936A1
· Chang et al.
· 2010
[cited by applicant]
US 20130123298A1
· Julia
· 2013
[cited by applicant]
US 20230181495A1
· Cope et al.
· 2023
[cited by applicant]
US 20240261240A1
· Cope et al.
· 2024
[cited by applicant]
US 20250195456A1
· Cope et al.
· 2025
[cited by applicant]
CN 102525895B
· 2013
[cited by applicant]
EP 3124005A1
· 2017
[cited by applicant]
EP 3110399B1
· 2018
[cited by applicant]
FR 2880807A1
· 2006
[cited by applicant]
JP 2006217975A
· 2006
[cited by applicant]
WO WO2004000219A2
· 2003
[cited by applicant]
WO WO2016013049
· 2016
[cited by applicant]
WO WO2021178946A1
· 2021
[cited by applicant]
Alain Borgeat, Expert Declaration review of US 2005/0070613, 5 pp. (Apr. 21, 2020).
[cited by applicant]
“Antioxidant Excipients.” Spectrum Chemical Mfg Corp (Aug. 1, 2023), http://www.spectrumchemical.com/chemical/antioxidant-excipients.
[cited by applicant]
Bathochromic Shift, Wikipedia Entry, downloaded from the Internet at: <https:en.wikipedia.org/w/index.php?title=Bathochromic_shift&oldid=761195798> 2pp, (last edited Jan. 21, 2017).
[cited by applicant]
Boomsma et al., Optimal collection and storage conditions for catecholamine measurements in human plasma and urine, Clin. Chem., 39(12):2503-8 (1993).
[cited by applicant]
Corona-Avendano et al., Study on the stability of noradrenaline and on the determination of its acidity constants, Spectrochim Acta A Mol Biomol Spectrosc., 61 (13-14):3139-44 (2005).
[cited by applicant]
D'Huart et al., “Physicochernical stability of norepinephrine bitartrate in polypropylene syringes at high concentrations for intensive care units”, Annales Pharmaceutiques Fran9a1ses, TT: pp. 212-221 (20″19).
[cited by applicant]
International Application No. PCT/US2021/021321, International Search Report and Written Opinion, mailed Aug. 12, 2021.
[cited by applicant]
International Application No. PCT/US2021/021321, Invitation to Pay Additional Fees, mailed Jun. 22, 2021.
[cited by applicant]
“LEVOPHED@—Norepinephrine Bitartrate Injection, USP, solution, concentrate”, Product Label, 5 pp., Hospira, Inc. (Jun. 2007).
[cited by applicant]
“LEVOPHED—norepinephrine bitartrate injection, solution, concentrate,” Product Label, 8 pp., Hospira, Inc. (Oct. 2020).
[cited by applicant]
Molla-Cantaveila et al., “Intravenous meropenern stability in physiological saline at room temperature”, Eur , J Hosp Phann, 21 pp. 202-207 (2014).
[cited by applicant]
“Noradrenaline (Norepinephrine) 1 mg/ml Concentrate for Solution for Infusion,” Summary of Product Characteristics, Hospira UK Ltd., 11 pp., downloaded from the Internet at: <http://www.medicines.org.uk/emc/product/4115…
[cited by applicant]
“Norepinephrine Bitartrate Injection, USP,” eCatalog Product Information 1 pp., Baxter Healthcare Corporation (Jul. 2019).
[cited by applicant]
“Norepinephrine Bitartrate Injection, USP,” Product Information Sheet, Baxter Healthcare Corporation, 6 pp. (Oct. 31, 2018).
[cited by applicant]
Parry et al., Physical and chemical considerations in the in vitro calibration of microdialysis probes for biogenic amine neurotransmitters and metabolites, J. Neurosci. Methods, 32(3): 175-83 (Jun. 1990). [abstract].
[cited by applicant]
Peddicord et al., Stability of High-Concentration Dopamine Hydrochloride, r-iorepinephrine Bitartrate, Epinephrine Hydrochloride, and t itroglycerin in 5% Dextrose Injection; 54 Am. J. Heal Th-System Pharmacy 1417 (1997…
[cited by applicant]
Rigamonti, “Study Report—Diluted Noradrenaline,” Sinetetica SA Via Penate 5 CH 6850 Mendrisio, 10 pp (Apr. 28, 2020).
[cited by applicant]
Rigamonti, “Study Report—Diluted Noradrenaline,” Sinetetica SA Via Penate 5 CH 6850 Mendrisio, 9 pp (Nov. 13, 2015).
[cited by applicant]
Sharma et al., “Hypotension”, StatPearls [Internet], CBI Bookshelf, Feb 1f-1, 2023.
[cited by applicant]
Tremblay et al., Stability of Norepinephrine Infusions Prepared in Dextrose and !'formal Saline Solutions, 55 Can. J. I\nesthesia 163 (2008).
[cited by applicant]
Walker et al., Stability of norepinephrine solutions in normal saline and 5% dextrose in water, Can. J. Hosp. Pharm., 63(2):113-8(2010).
[cited by applicant]
Williams et al., A comparison of drug substance predicted chemical stability with ICH compliant stability studies, Drug Dev. Ind. Pharm, 45(3):379-86 (2019).
[cited by applicant]
New York General Hospital Adult Parenteral Guidelines, Mar. 1999, Revised Dec. 2020.
[cited by applicant]
ASHP IV Adult Continuous Infusion Guidelines, version 1.01, Nov. 2016.
[cited by applicant]
Excerpt from Wikipedia on “Blow fill seal” (May 30, 2017).
[cited by applicant]
Rowe, Raymond C. “Dextrose” Handbook of Pharmaceutical Excipients, pp. 222-225. Pharmaceutical Press, 2009. ProQuest Ebook Central, https://ebookcentral. proquest. com/lib/uspto-ebooks/detail .action?docl 0=4967873. (Ye…
[cited by applicant]